{"id":590884,"date":"2022-03-11T18:44:01","date_gmt":"2022-03-11T18:44:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=590884"},"modified":"2022-03-11T18:44:01","modified_gmt":"2022-03-11T18:44:01","slug":"higherrisk-chronic-myelomonocytic-leukemia-market-analysis-pipeline-epidemiology-treatment-drugs-companies-by-delveinsight-sensei-biotherapeutic-argenx-novartis-kura-oncology-takedaothers","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/higherrisk-chronic-myelomonocytic-leukemia-market-analysis-pipeline-epidemiology-treatment-drugs-companies-by-delveinsight-sensei-biotherapeutic-argenx-novartis-kura-oncology-takedaothers_590884.html","title":{"rendered":"Higher-Risk Chronic Myelomonocytic Leukemia Market Analysis, Pipeline, Epidemiology, Treatment, Drugs, Companies by DelveInsight | Sensei Biotherapeutic, Argenx, Novartis, Kura Oncology, Takeda,others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1646992223.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Higher-Risk Chronic Myelomonocytic Leukemia Market Analysis, Pipeline, Epidemiology, Treatment, Drugs, Companies by DelveInsight | Sensei Biotherapeutic, Argenx, Novartis, Kura Oncology, Takeda,others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1646992223.jpeg\" alt=\"Higher-Risk Chronic Myelomonocytic Leukemia Market Analysis, Pipeline, Epidemiology, Treatment, Drugs, Companies by DelveInsight | Sensei Biotherapeutic, Argenx, Novartis, Kura Oncology, Takeda,others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Higher-Risk Chronic Myelomonocytic Leukemia Market<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s &ldquo;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/higher-risk-chronic-myelomonocytic-leukemia-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Higher-Risk Chronic Myelomonocytic Leukemia Market<\/a>&nbsp;Insights, Epidemiology, and Market Forecast-2030<\/strong>&Prime;&nbsp;report delivers an in-depth understanding of the Higher-Risk Chronic Myelomonocytic Leukemia , historical and forecasted epidemiology as well as the Higher-Risk Chronic Myelomonocytic Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some facts of&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/higher-risk-chronic-myelomonocytic-leukemia-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Higher Risk Chronic Myelomonocytic Leukemia Market<\/a>&nbsp;are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>CMML affects approximately 3 out of 100,000 individuals in the United States each year.<\/li>\n<li>The risk of CMML increases with age. This disease is rare in those younger than 40, with most cases found in people 60 and older.<\/li>\n<li>Median survival of patients with CMML is reported to be approximately 12 to 40 months.<\/li>\n<li>Through various secondary studies it can be concluded that overall HR-CMML affects more males than females.<\/li>\n<li>The disease incidence rate ranges between 3.5 and 4.1\/1 000 000 per year in the United States and in Europe.<\/li>\n<li>On an average, patients with CMML demonstrate ~10-15 mutations per kilobase of coding DNA regions, similar to patients with acute myeloid leukemia (AML), but several folds lower than other malignancies such as melanoma and lung cancer.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/higher-risk-chronic-myelomonocytic-leukemia-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/higher-risk-chronic-myelomonocytic-leukemia-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of&nbsp;Higher Risk Chronic Myelomonocytic Leukemia companies&nbsp;are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Pharmion Corporation<\/li>\n<li>Otsuka America Pharmaceutical<\/li>\n<li>Argenx<\/li>\n<li>Novartis<\/li>\n<li>Kura Oncology<\/li>\n<li>Sensei Biotherapeutics<\/li>\n<li>Takeda<\/li>\n<li>Humanigen<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Chronic Myelomonocytic Leukemia&nbsp;(CMML) is a rare, clonal hematopoietic stem cell disorder characterized by the presence of sustained (&gt;3 months) peripheral blood (PB) monocytosis (&ge;1 &times; 109\/L; monocytes &ge;10% of white blood cell count) along with dysplastic features in the bone marrow (BM). CMML has some similarities with a condition called myelodysplastic syndrome (MDS) and some resemblance to a group of conditions called myeloproliferative neoplasms (MPN). It is classified as being a mixture of these two conditions.<\/p>\n<p style=\"text-align: justify;\">CMML shares clinical and biological features with MDS, including cytopenia and bone marrow failure, risk of progression to AML, and overlapping, recurring, cytogenetic abnormalities.<\/p>\n<p style=\"text-align: justify;\">CMML can be further subdivided into two categories depending on the number of blasts found in the peripheral blood and bone marrow, CMML-1 with less than 5% blasts in peripheral blood and less than 10% in bone marrow, and CMML-2 with 5 to 19% blasts in peripheral blood and\/or 10 and 19% in the bone marrow.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/higher-risk-chronic-myelomonocytic-leukemia-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Higher Risk Chronic Myelomonocytic Leukemia therapies<\/a>&nbsp;are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Vidaza<\/li>\n<li>Dacogen<\/li>\n<li>Cusatuzumab<\/li>\n<li>MBG453<\/li>\n<li>Tipifarnib<\/li>\n<li>SNS-301<\/li>\n<li>Pevonedistat<\/li>\n<li>Lenzilumab<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/higher-risk-chronic-myelomonocytic-leukemia-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/higher-risk-chronic-myelomonocytic-leukemia-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Key Insights<\/li>\n<li>Executive Summary of Higher-Risk Chronic Myelomonocytic Leukemia<\/li>\n<li>Competitive Intelligence Analysis for Higher-Risk Chronic Myelomonocytic Leukemia<\/li>\n<li>Higher-Risk Chronic Myelomonocytic Leukemia : Market Overview at a Glance<\/li>\n<li>Higher-Risk Chronic Myelomonocytic Leukemia : Disease Background and Overview<\/li>\n<li>Patient Journey<\/li>\n<li>Higher-Risk Chronic Myelomonocytic Leukemia Epidemiology and Patient Population<\/li>\n<li>Treatment Algorithm, Current Treatment, and Medical Practices<\/li>\n<li>Unmet Needs<\/li>\n<li>Key Endpoints of Higher-Risk Chronic Myelomonocytic Leukemia Treatment<\/li>\n<li>Marketed Products<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">List to be continued in report<\/p>\n<ol style=\"text-align: justify;\" start=\"12\">\n<li>Emerging Therapies<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">List to be continued in report<\/p>\n<ol style=\"text-align: justify;\" start=\"13\">\n<li>Higher-Risk Chronic Myelomonocytic Leukemia : Seven Major Market Analysis<\/li>\n<li>Attribute analysis<\/li>\n<li>7MM: Market Outlook<\/li>\n<li>Access and Reimbursement Overview of Higher-Risk Chronic Myelomonocytic Leukemia<\/li>\n<li>KOL Views<\/li>\n<li>Market Drivers<\/li>\n<li>Market Barriers<\/li>\n<li>Appendix<\/li>\n<li>DelveInsight Capabilities<\/li>\n<li>Disclaimer<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Delveinsight:&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight Business Research is a leading&nbsp;Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=higherrisk-chronic-myelomonocytic-leukemia-market-analysis-pipeline-epidemiology-treatment-drugs-companies-by-delveinsight-sensei-biotherapeutic-argenx-novartis-kura-oncology-takedaothers\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/higher-risk-chronic-myelomonocytic-leukemia-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/higher-risk-chronic-myelomonocytic-leukemia-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/higher-risk-chronic-myelomonocytic-leukemia-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=higherrisk-chronic-myelomonocytic-leukemia-market-analysis-pipeline-epidemiology-treatment-drugs-companies-by-delveinsight-sensei-biotherapeutic-argenx-novartis-kura-oncology-takedaothers\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Higher-Risk Chronic Myelomonocytic Leukemia Market DelveInsight&rsquo;s &ldquo;Higher-Risk Chronic Myelomonocytic Leukemia Market&nbsp;Insights, Epidemiology, and Market Forecast-2030&Prime;&nbsp;report delivers an in-depth understanding of the Higher-Risk Chronic Myelomonocytic Leukemia , historical and forecasted epidemiology as well as the Higher-Risk Chronic Myelomonocytic Leukemia market trends &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/higherrisk-chronic-myelomonocytic-leukemia-market-analysis-pipeline-epidemiology-treatment-drugs-companies-by-delveinsight-sensei-biotherapeutic-argenx-novartis-kura-oncology-takedaothers_590884.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-590884","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/590884","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=590884"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/590884\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=590884"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=590884"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=590884"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}